Treating Attention-Deficit/Hyperactivity Disorder Matters.
作者信息
Levin Frances R, Hernandez Mariely, Mariani John J
机构信息
Division on Substance Use Disorders, New York State Psychiatric Institute, New York, New York.
Department of Psychiatry, Columbia University Irving Medical Center, New York, New York.
出版信息
JAMA. 2024 Mar 12;331(10):831-833. doi: 10.1001/jama.2024.1755.
Abstract
摘要
相似文献
1
Treating Attention-Deficit/Hyperactivity Disorder Matters.
JAMA. 2024 Mar 12;331(10):831-833. doi: 10.1001/jama.2024.1755.
2
Attention deficit hyperactivity disorder in adults: what the non-specialist needs to know.
Br J Hosp Med (Lond). 2020 Mar 2;81(3):1-11. doi: 10.12968/hmed.2019.0188. Epub 2020 Mar 16.
3
Attention-deficit/hyperactivity disorder: etiology and pharmacotherapy.
Arch Iran Med. 2006 Oct;9(4):374-80.
4
Predicting substance use disorder using long-term attention deficit hyperactivity disorder medication records in Truven.
Health Informatics J. 2020 Jun;26(2):787-802. doi: 10.1177/1460458219844075. Epub 2019 May 19.
5
A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder.
Nord J Psychiatry. 2015 May;69(4):241-8. doi: 10.3109/08039488.2014.972975. Epub 2014 Nov 21.
6
Attention-deficit/hyperactivity disorder: how much responsibility are pediatricians taking?
Pediatrics. 2009 Jan;123(1):248-55. doi: 10.1542/peds.2007-3198.
7
Psychopharmacotherapy of Attention Deficit-Hyperactivity Disorder in Children with Comorbid Conditions.
Pediatr Neurol. 2018 May;82:7-12. doi: 10.1016/j.pediatrneurol.2017.09.010. Epub 2017 Sep 27.
8
Attention Deficit Hyperactivity Disorder in Preschool-Age Children.
Child Adolesc Psychiatr Clin N Am. 2017 Jul;26(3):523-538. doi: 10.1016/j.chc.2017.02.007.
9
Cardiovascular considerations of attention deficit hyperactivity disorder medications: a report of the European Network on Hyperactivity Disorders work group, European Attention Deficit Hyperactivity Disorder Guidelines Group on attention deficit hyperactivity disorder drug safety meeting.
Cardiol Young. 2012 Feb;22(1):63-70. doi: 10.1017/S1047951111000928. Epub 2011 Jul 19.
10
Positive association between attention-deficit/ hyperactivity disorder medication use and academic achievement during elementary school.
Pediatrics. 2009 May;123(5):1273-9. doi: 10.1542/peds.2008-1597.
引用本文的文献
1
Recent Trends in Medication Treatment for Attention-Deficit Hyperactivity Disorder.
Psychiatr Serv. 2025 May 28:appips20240574. doi: 10.1176/appi.ps.20240574.
本文引用的文献
1
ADHD Pharmacotherapy and Mortality in Individuals With ADHD.
JAMA. 2024 Mar 12;331(10):850-860. doi: 10.1001/jama.2024.0851.
2
Trends in Use of Telemedicine for Stimulant Initiation Among Children and Adults.
Psychiatr Serv. 2024 Jul 1;75(7):630-637. doi: 10.1176/appi.ps.20230421. Epub 2024 Jan 19.
3
Trends in Incident Prescriptions for Behavioral Health Medications in the US, 2018-2022.
JAMA Psychiatry. 2024 Apr 1;81(4):396-405. doi: 10.1001/jamapsychiatry.2023.5045.
4
ADHD medication discontinuation and persistence across the lifespan: a retrospective observational study using population-based databases.
Lancet Psychiatry. 2024 Jan;11(1):16-26. doi: 10.1016/S2215-0366(23)00332-2. Epub 2023 Nov 27.
5
Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases.
JAMA Psychiatry. 2024 Feb 1;81(2):178-187. doi: 10.1001/jamapsychiatry.2023.4294.
6
Sudden Increases in U.S. Stimulant Prescribing: Alarming or Not?
J Atten Disord. 2023 Apr;27(6):571-574. doi: 10.1177/10870547231164155. Epub 2023 Mar 22.
7
Functional Impairments Associated With ADHD in Adulthood and the Impact of Pharmacological Treatment.
J Atten Disord. 2023 May;27(7):669-697. doi: 10.1177/10870547231158572. Epub 2023 Mar 6.
8
Pharmacotherapy for Attention-Deficit/Hyperactivity Disorder and Retention in Outpatient Substance Use Disorder Treatment: A Retrospective Cohort Study.
J Clin Psychiatry. 2021 Feb 23;82(2):20m13598. doi: 10.4088/JCP.20m13598.
9
Pharmacologic Treatment of Attention Deficit-Hyperactivity Disorder.
N Engl J Med. 2020 Sep 10;383(11):1050-1056. doi: 10.1056/NEJMra1917069.
10
Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases.
Biol Psychiatry. 2019 Sep 1;86(5):335-343. doi: 10.1016/j.biopsych.2019.04.009. Epub 2019 Apr 17.
Zotero 插件